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Abstract 
The use of solid dispersion techniques to modify physicochemical properties and improve solubility 
and dissolution rate may result in alteration to electrostatic properties of particles. Particle 
triboelectrification, plays an important part in powder processing, affecting end product quality due 
to particle deposition and powder loss. This study investigates the use of glucosamine 
hydrochloride (GLU) in solid dispersions with indomethacin. Solvents selected for the preparation 
of the dispersions were acetone, acetone-water, ethanol and ethanol-water. Solid state 
characterizations (DSC, FTIR and XRPD) and dissolution were conducted. Dispersions were 
subjected to charging using a custom built device based on a shaking concept, consisting of a 
Faraday cup connected to an electrometer. All dispersions improved the dissolution rate of 
indomethacin. Analysis showed the method of preparation of the dispersion induced polymorphic 
forms of the drug. Indomethacin had a high propensity for charging (-411 nC/g). GLU had a very 
low charge (-1 nC/g). All dispersions had low charges (-1 to 14 nC/g). Acetone as a solvent, or in 
combination with water, produced samples with an electronegative charge in polarity. The same 
approach with ethanol produced electropositive charging. The results show the selection of solvents 
can influence powder charge thereby improving powder handling as well as dissolution properties. 
Keywords: Electrostatics; Solid dispersions; Triboelectrification; Indomethacin; D-glucosamine 
HCl; Polymorphism. 
Abbreviations: GLU, glucosamine hydrochloride; DSC, differential scanning calorimetry; XRPD, 
x-ray powder diffraction; FTIR, Fourier transform infra-red; BCS, biopharmaceutical classification 
system; CBZ, carbamazepine; PXM, piroxicam; IBU, ibuprofen; IND, indomethacin; NSAID, non-
steroidal anti-inflammatory drug; A, acetone; A/W, acetone-water; E, ethanol; E/W, ethanol-water; 
SEM, scanning electron microscopy; DE, dissolution efficiency; MDT, mean dissolution time; 
MDR, mean dissolution rate; ATR, attenuated total reflection; RH, relative humidity; PSD, particle 
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size distribution; USP, United States pharmacopeia; PM, physical mixture; VIBRI, vibratory 
feeder; HELOS, Helium-Neon laser Optical System.  
 
 
Graphical Abstract 
 
Dissolution and tribo-electrification of indomethacin: glucosamine solid dispersions 
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1. Introduction 
Biopharmaceutical Classification System (BCS) class II drugs are characterized by high membrane 
permeability and low aqueous solubility. This poor aqueous solubility is problematic in 
pharmaceutical development and seems to be more prevalent with new drug entities (Al-Hamidi et 
al., 2010a; Baird and Taylor 2012; Fahr and Liu 2007). The solubility and dissolution rate of drugs 
in this category are key factors in determining their rate and extent of absorption from the 
gastrointestinal tract. As dissolution rates are typically the rate limiting step for bioavailability, their 
enhancement is often vital to attaining suitable blood concentrations for therapeutic effect. 
There are several methods employed to aid the improvement of the dissolution rate of BCS class II 
drugs. The most common method involves particle size reduction using high pressure milling 
methods with the view of increasing the surface area (Rabinow, 2004; Valizadeh et al., 2004). The 
drawback with this method is the requirement for high energy input. Moreover, the product 
obtained after such high energy input is likely to increase affinity for electrostatic charging, leading 
to particle agglomeration and broad particle size distributions. Other methods used include 
complexation (Loftsson and Duchene, 2007), liquisolid techniques (Javadzadeh et al., 2007; 
Nokhodchi et al., 2005), salt formation (Berge et al., 1977; David et al., 2012) and solid dispersions 
(Al-Hamidi et al., 2010a). Despite limitations such as cost and scale up with solid dispersions, 
adoption of cost-effective solvents along with method modifications can be selected to minimise 
these.  
Solid dispersion formation is one of the most effective methods of improving dissolution and has 
had much interest in recent years (Al-Hamidi et al., 2010a, Baird and Taylor 2012). The increased 
solubility and dissolution rate of drugs in solid dispersions could be the result of a reduction in 
particle size down to submicron (1-100 nm) levels (Manikandan et al., 2012), conversion from 
crystalline to amorphous form and the improved wettability of the drug particle by the dissolved 
hydrophilic carrier (Leuner and Dressman 2000).  
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Glucosamine is a popular nutritional supplement for both humans and dogs and naturally occurring 
glucosamine has been shown to decrease pain and improve mobility in osteoarthritic joints of 
humans when given orally (da Camara and Dowless 1998; Pujalte et al., 1980). The incorporation 
of glucosamine HCl (GLU) into formulations may give additional benefit to patients requiring anti-
inflammatory drugs, due to glucosamine’s ability to decrease pain and improve mobility in 
osteoarthritic joints. Al-Hamidi et al. (2010a) showed it enhanced the dissolution rate of 
carbamazepine (CBZ) from solid dispersion formulations when used as a hydrophilic carrier.  Al 
Hamidi et al. (2014, 2013, 2010b) also showed that the incorporation of glucosamine in ground 
piroxicam (PXM), ibuprofen (IBU) or CBZ  mixtures co-ground together, significantly increased 
the dissolution rates of the respective drugs. They also showed that increasing the grinding time 
resulted in polymorphic transformation of the drugs (CBZ and PXM). Indomethacin (IND) is a non-
steroidal anti-inflammatory drug (NSAID). NSAIDs are widely used for rheumatoid arthritis, 
osteoarthritis and a variety of other acute and chronic musculoskeletal disorders, dysmenorrhea and 
as ordinary analgesics (Andersson et al., 1998; Montvale 2002). Indomethacin was selected as a 
model BCS class II compound due to its low solubility to establish the efficiency of the solid 
dispersion method employed in this work. 
The use of solid dispersion techniques to modify physicochemical properties to improve solubility 
and dissolution rate may also result in changes in the electrostatic properties of particles. Particle 
triboelectrification plays an important part in powder processing affecting end product quality due 
to particle deposition and powder loss. It has been shown to give rise to segregation of binary 
mixtures (Šupuk et. al., 2011); however, very little work has been done to understand electrostatic 
charging characteristics of powders produced from solid dispersions. 
In pharmaceutical processes, triboelectrification refers to a method of particle electrification which 
can take place during powder handling operations. Such charging can be regarded as a solid state 
electrochemistry, where there is no transport medium (electrolyte) and their action depends solely 
on physical contact (Matsusaka et al., 2010). Although, the exact charge transfer mechanisms in 
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dielectric materials are still ambiguous, fundamental studies on charge transfer between an 
elastic sphere and a metal plate have shown the charge transfer to be completed during the 
unloading stage of the elastic deformation following the impact (Matsusaka et al., 2000). 
Therefore, essential pharmaceutical processes such as high-shear granulation are likely to 
influence the magnitude of charge generated as processing parameters are shown to affect the 
strength and size distribution of resulting granules (Rahmanian et al., 2008, 2011). 
Furthermore, pharmaceutical powders are usually insulators and have a relatively small particle 
size and low bulk density, thus providing ideal conditions for tribo-electric charging (Šupuk et. al., 
2012). Supuk et al. (2013) studied the impact of the counter ion on electrostatic charge of 
flurbiprofen salts. The results showed the magnitude of charge and polarity of the flurbiprofen salts 
to be highly dependent on the type of counter ion selected for the salt formation. Ghori et al. (2014) 
also found cellulose ethers to reduce the charging of flurbiprofen thereby improving its flow and 
compaction properties. 
The objective of this study was to produce indomethacin:glucosamine solid dispersions to 
investigate the role of solvent (ethanol and acetone and their binary mixtures with water) on 
dissolution enhancement and electrostatic properties. Triboelectric properties of the solid 
dispersions were investigated using a custom built tribo-electric device based on a shaking concept. 
The present work was conducted to determine whether solid dispersions could improve the 
dissolution profiles and to understand their effect on charging characteristics of the indomethacin-
glucosamine dispersions. 
 
2. Materials and Methods 
2.1. Materials 
Indomethacin (γ-form) and D-(+)-glucosamine hydrochloride (GLU) were purchased from Sigma 
(UK). The solvents were of analytical grade and all the materials were used as obtained. The 
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dissolution medium (pH 7.2) was prepared according to the USP 2003 method using the following 
materials: potassium phosphate monobasic-white crystals and sodium hydroxide (Sigma (UK)). 
 
2.2. Hansen’s solubility parameter 
The Hansen solubility parameter (δ) was calculated for indomethacin and glucosamine by 
considering their chemical structure (Hansen 1969). This was used to predict the miscibility of both 
the drug and carrier. The Hoftyzer-Van Krevelen method described below was used in the 
determination of the drug/carrier miscibility (Gupta et al., 2011; Hansen 1969; Hoftyzer and 
Krevelen, 1976; Manniruzziman et al., 2014). 
�� =  �ܨ���  , ሺ��ܝ�ܜ�ܗܖ ૚ሻ;  �� =    ሺ�ܨ��ሻ0.5�  , ሺ��ܝ�ܜ�ܗܖ ૛ሻ;  �ℎ = ሺ �ܧℎ��  ሻ0.5, ሺ��ܝ�ܜ�ܗܖ ૜ሻ 
and 
��2 =  �� 2 +  ��2 +  �ℎ2, ሺ��ܝ�ܜ�ܗܖ ૝ሻ 
 
Where Fdi and Fpi are molar attraction constants due to dispersion (J
1/2
.cm
3/2
.mol
-1
) and polar 
(J
1/2
.cm
3/2
.mol
-1
) components respectively and Ehi is the hydrogen bonding energy (J/mol). δd, δp 
and δh are the dispersive (MPa1/2), electrostatic polar (MPa1/2) and hydrogen bonding forces 
(MPa
1/2
) respectively with V  being the molar volume (cm
3
/mol). δt is known as the total solubility 
parameter also known as the Hansen solubility parameter. The molar volume of the drug and carrier 
were calculated based on their density and molecular weight, as determined from literature. 
2.3. Preparation of physical mixtures of drug-carrier 
Physical mixtures of indomethacin were prepared by mixing indomethacin and D-(+)-glucosamine 
hydrochloride in a Turbula blender (Type T2 C, Switzerland) for 10 min. Different ratios of 
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drug:carrier (2:1, 1:3, 1:5 and 1:10) were prepared for comparison. The powders were stored in 
screw-capped glass vials in a desiccator until required after the mixing process. 
 
2.4. Preparation of solid dispersions of drug-carrier 
The conventional solvent evaporation technique was employed in the preparation of the different 
ratios of drug to carrier (2:1, 1:3, 1:5 and 1:10). The drug was dissolved in either acetone (A) or 
ethanol (E) (30 ml) followed by the dispersion of GLU at appropriate amounts. The solvents were 
removed during continuous stirring at 200 rpm at 40 

C for 24 hours. A second technique used 
involved dissolving the drug in 20 ml of solvent (either acetone or ethanol) and the carrier in 10 ml 
of water (abbreviations used are A/W for acetone and water binary mixture and E/W for ethanol and 
water binary mixture). The carrier solution was then added to the drug solution under the same 
conditions described previously until the dry solid dispersions were obtained. The dispersions 
obtained were again stored in a desiccator until required. 
2.5. Electrostatic properties of physical mixture and solid dispersions 
A triboelectric device based on a shaking concept, previously described by Šupuk and co-workers 
(2009) and detailed elsewhere (Asare-Addo et al., 2013a; Supuk et al., 2013), was used to 
investigate the triboelectrification of drug, glucosamine and solid dispersion powders by 
determining the charge-to-mass ratio. In this work, the charge-to-mass ratio of drug, glucosamine 
and solid dispersion powders was measured following shaking using a custom made Faraday cup 
connected to an electrometer (Keithley Model 6514).  
In brief, a 100 mg indomethacin-glucosamine sample was weighed and initial charge (at time 0 
min) obtained using the Faraday cup and an electrometer. The sample was then placed inside a 
stainless steel container and subjected to shaking for a predetermined time (0.5, 2, 5 or 10 minutes) 
at 20 Hz to induce the triboelectrification effect. The final charge and polarity post tribo-
electrification were measured by the Faraday cup and an electrometer. The container was then 
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tapped to remove any particles adhered to the walls. The weight of the sample was measured to 
account for mass loss to the container walls due to adhesion. Tests were carried out under ambient 
temperature (22 ± 1ºC) and relative humidity of 35-47 %RH. 
 
2.6. Solid State Studies 
Particle Size Analysis  
The Sympatec laser diffraction particle size analyser (Clausthal-Zellerfeld, Germany) was used in 
the determination of the particle size distribution of the formulations. The procedure was as follows: 
about 2–3 g of the sample was transferred into the funnel of the VIBRI (vibratory feeder). The 
sample container was cautiously tapped against the funnel to ensure all the content was transferred. 
A test reference measurement was performed with the Helium-Neon laser Optical System 
(HELOS) (HELOS/KR, Sympatec GmbH, Clausthal-Zellerfeld, Germany) sensor using 
WINDOX software (version 5.4.0.0, Sympatec GmbH, Clausthal-Zellerfeld, Germany) 
followed by a standard measurement. 
Scanning electron microscopy (SEM) 
Electron micrographs were obtained using a scanning electron microscope (Jeol JSM-6060CV 
SEM) operating at 10 kV. The samples were mounted on a metal stub with double-sided adhesive 
tape and were sputter-coated with an ultra-thin coating of gold/palladium (80:20) for 60 s using a 
Quorum SC7620 Sputter Coater under vacuum with gold in an argon atmosphere prior to 
observation. Micrographs with different magnifications were taken to facilitate the study of the 
morphology of the solid dispersions. 
Fourier transform infrared (FTIR) 
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A 5-10 mg sample of drug, carrier and solid dispersions (ratio 1:3 in acetone and in ethanol) and 
those of the binary mixtures (acetone and water or ethanol and water) were placed on an Attenuated 
Total Reflection (ATR) plate and analysed using FTIR spectroscopy (Nicolet 380 FT-IR 
spectrometer, ThermoElectron Corporation, USA). All samples were analysed by measuring the 
transmittance of infrared wavelengths of the electromagnetic spectrum of the sample in the range of 
400–4000 cm−1. 
Differential scanning calorimetry (DSC) 
Samples of solid dispersions or physical mixtures of drug:carrier (3-6 mg) was placed in standard 
aluminium pans (40 µL) with a vented lid. The crimped aluminium pans were heated from 20 to 
250 ˚C at a scanning rate of 10 °C/min using nitrogen gas as a purge gas in a DSC 1 (Mettler-
Toledo, Switzerland). The enthalpy, onset temperatures and melting points of the samples were 
obtained using the software provided. 
X-ray powder diffraction (XRPD) 
The XRPD patterns of pure indomethacin, glucosamine and indomethacin-glucosamine solid 
dispersions were obtained using a Bruker D2 Phaser XRPD diffractometer. The samples were 
scanned from 5
◦
 to 100
◦ 
2  at a rate of 1.5◦ min−1. 
2.7. Dissolution studies 
USP dissolution apparatus I was used to monitor the dissolution profiles of indomethacin, 
indomethacin-glucosamine physical mixtures and solid dispersions. All formulations for the 
dissolution process contained the same amount of indomethacin (25 mg).  The powder samples, 
after weighing, were introduced into the dissolution basket. The baskets had filter paper placed at 
the base to prevent the powder falling through the pores of the basket. The dissolution medium was 
a pH 7.2 buffer (900 mL) equilibrated to 37 °C ± 0.5 °C. The baskets were rotated at 50 rpm. 
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Samples were withdrawn at selected time intervals (5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105 and 
120 min) using a peristaltic pump and the concentrations of indomethacin in the samples 
determined by UV spectrophotometer at 318 nm. All dissolution tests were carried out in triplicate. 
2.8. Dissolution parameters 
As an independent metric, the mean percentage of drug dissolved in the first 10 min (Q10min) and 30 
min (Q30min) were used to represent the dissolution rate from various preparations. The dissolution 
efficiency (DE) of a pharmaceutical dosage form is defined as the area under the dissolution curve 
up to the time, t, expressed as the percentage of the area of the rectangle (Khan, 1975) as detailed 
elsewhere (Asare-Addo et al., 2013b; Siahi-Shadbad et al., 2011).  
 
DE (%) =                                                                                                                                            (Equation 5)
 
where y is the percentage (%) of drug dissolved at time t (min). 
Another approach to obtain a parameter that describes the dissolution rate is the mean dissolution 
time (MDT). This parameter is the most likely time taken for a molecule to be dissolved from a 
solid dosage form. In other words, MDT is the mean time for the drug to dissolve under in vitro 
dissolution conditions and is calculated using the following equation: 
MDT (min) =  

n
j
j
n
j
jj
M
Mt
1
1
 (Equation 6) 
where j is the sample number, tj is the midpoint of the jth time period (calculated with ((t + t-1)/2) 
and Mj is the additional amount of drug dissolved between tj and t-1. 
%100
100
0 

ty
dty
DE
t
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The mean dissolution rate (MDR) can be calculated according to the following equations: 
MDR (%min
-1
) = 
n
tM
n
j
j 1 /
  (Equation 7) 
where n is the number of dissolution sample times, t is the time at the midpoint between t and t-1 
(easily calculated with [t + (t-1)/2]. 
 
3. RESULTS AND DISCUSSION 
3.1. Solubility parameters and SEM 
The Hansen solubility parameter was estimated using the Hoftyzer-Van Krevelen approach to 
predict the miscibility of indomethacin and glucosamine (Table 1). Several other authors have used 
this method in predicting the miscibility of drugs and excipients (Forster et al., 2001; Greenhalgh et 
al., 1999; Hancock et al., 1997; Manniruzziman et al 2014; Suzuki and Sanada, 1997). Compounds 
with similar values of δ or Δδ < 7 MPa1/2 are likely to be miscible with compound with Δδ > 10 
MPa 
1/2
 immiscible (Forster et al., 2001). The Δδ value obtained for indomethacin and glucosamine 
was 15.93 MPa
1/2
 suggesting that the two components were immiscible. This further evidenced in 
the SEM images in Figure 1(d and g) where indomethacin particles can be seen in pockets or 
adhering to the surfaces of glucosamine. 
3.2. Solid state studies of solid dispersions and physical mixtures 
FTIR spectra for indomethacin samples are shown in Figure 2. It has been shown that indomethacin 
has two monotropic polymorphs, γ (which is the most stable form) and α (which is a metastable 
form) (Borka 1974; Yamamoto, 1968). FTIR spectroscopy was carried out on several formulations 
to ascertain whether any possible structural changes occurred at the molecular level. According to 
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existing literature, the most characteristic difference between the two main polymorphic forms of 
indomethacin is at the 1700 cm
-1
 region, where CO-bonds shift within the spectrum of each 
polymorph (Greco and Bogner, 2010). This suggested involvement of the carbonyl group in 
different types of hydrogen bonds in the establishment of the crystal lattice of the two structures. 
The spectrum of commercial untreated indomethacin proves the characteristic bands of the drug at 
3000 cm
-1
 (aromatic C-H stretch), 1719 cm
-1
 (ketone C=O stretch), 1593 cm
-1
 (aromatic C=C 
stretch), 1457 cm
-1
 (O-CH3 deformation), 1230 cm
-1
 (C-O stretch plus O-H deformation), 927 cm
-1
 
(carboxylic O-H deformation), and 754 cm
-1
 (C-Cl vibration). The solid dispersion of 
indomethacin:glucosamine prepared from ethanol/water exhibited similar IR spectra to untreated 
indomethacin (Figure 2e). The same peaks at the same wavenumbers are seen for untreated 
indomethacin while solid dispersions prepared from acetone, ethanol and acetone/water exhibited 
different IR spectra. This indicates that the solid dispersions prepared from ethanol/water were not 
associated with changes at the molecular level, whereas extra bands between 1600 and 1800 cm
-1
 
appeared for the solid dispersions prepared from acetone, ethanol and acetone/water (Figure 2). It 
has been shown that α-form exhibits absorption events at 1735, 1688, 1681 and 1649 cm-1, whereas 
γ-form shows bands at 1717 and 1692 cm-1. In case of the presence of amorphous form, two bands 
at 1710 and 1684 should appear (Taylor and Zografi, 1997). FT-IR results showed that solid 
dispersions prepared from acetone, ethanol and acetone/water are mixtures of α and γ forms. 
To confirm the results obtained by FTIR, XRPD was carried out on pure indomethacin, solid 
dispersions of indomethacin-glucosamine prepared from the different solvents and the physical 
mixtures of indomethacin-glucosamine HCl. The results are presented in Figure 3. It has been 
shown that major distinctive peaks for identification of γ-form are 11.6, 16.8, 19.6, 21.8 and 26.6◦ 
2θ, whereas these 2θ for α-form are 8.4, 14.4, 18.5 and 22◦.  The peaks shown in Figure 3 indicate 
that the pure indomethacin is γ-indomethacin. These spectra are in agreement with the 
corresponding polymorph reported elsewhere (Kaneniwa et al., 1985; Okumura et al., 2006). The 
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presence of some peaks relating to the γ-form in the solid dispersion samples prepared from 
acetone, ethanol and acetone/water is indicative of the formation of mixtures of γ- and α- forms. 
DSC can be used to reflect miscibility by a shift in the melting endotherm of drug, glass transition 
temperature changes for amorphous systems or both as reported by several authors (Ford and 
Timmins 1987; Gupta et al., 2011; Mura et al., 1998; Shamblin et al., 1998) and can be used to 
identify different polymorphs of indomethacin (Crowley and Zografi 2002). Figure 4 depicts the 
DSC traces of indomethacin, its physical mixture with glucosamine and solid dispersions of 
indomethacin:glucosamine at scanning rate of 10 ºC/min for the 1:3 ratio. Indomethacin displayed 
an endothermic peak at ~161.26 ºC corresponding to its melting point. Glucosamine melted at ~210 
ºC and the DSC traces for the physical mixture of indomethacin and glucosamine showed no 
changes in their thermal behaviour (Figure 4). The same was observed for the solid dispersion 
sample prepared from ethanol/water. This was similar to the results obtained by FTIR or XRPD. 
Figure 4 shows the sharp endothermic peak at ~210 ºC corresponding to the melting of glucosamine 
for all formulations indicating immiscibility. The absence of any melting point depression was 
expected due to the immiscible nature of the solid dispersions as the chemical potential of the 
indomethacin remained unchanged or unaltered in the glucosamine (Gupta et al., 2011). This was 
true for all the ratios of the drug studied. The results also showed that in the case of solid 
dispersions prepared from acetone, ethanol and acetone/water, an extra endothermic peak was 
observed before the main endothermic transformation for the γ-form (Figure 4). This small peak 
around 154 ºC is an indication of the presence of α-form of indomethacin as a result of the solvent 
used. This polymorphic form could impact dissolution (covered under dissolution section) and 
triboelectrification. 
3.3 Triboelectrification studies 
The triboelectrification results showed pure indomethacin to have a great propensity for tribo-
electric charging (-411 nC/g) and a resulting particle adhesion to stainless steel wall (82 %) (Figures 
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5 and 6). Pure glucosamine had practically no charge (-1 nC/g). The net charging behaviour of the 
physical mixture, and all the solid dispersions of indomethacin:glucosamine, was shown to be low 
regardless of the type of solvent used or the method used in generating the solid dispersions. The 
low net charge of the physical mixture (-5 nC/g) implied ordered mixing so that particles of 
opposite charges adhered to each other. This also shows glucosamine’s potential to reduce the high 
charge of indomethacin thereby improving its handling. The results also showed that acetone as a 
solvent, or in combination with water, produced samples with a charge that was electro negative in 
polarity. On the other hand, when ethanol was used with the same approach, the polarity of charge 
was electro positive (Figure 5). The net charges of the resultant solid dispersions were however 
slightly increased when water was used as a binary solvent for both acetone and ethanol. The results 
suggest that one can manipulate the charge of solid dispersions, depending on the solvent used, to 
improve triboelectrification properties.  The mass loss of all samples tested was shown to be low 
regardless of the type of solvent (Figure 6). The lowest level of net charge, and particle adhesion, of 
the solid dispersions tested was obtained when acetone was used as a single solvent.  As a result, 
further work is in progress to analyse the effect of different solvents and solvent mixture 
compositions in generating solid dispersions on the electrostatic properties of other drug-
glucosamine dispersions (with other carriers being investigated to determine if this phenomenon 
occurs with both miscible and immiscible systems). 
3.4. Dissolution studies 
Indomethcin:glucosamine solid dispersions, prepared under different conditions, were subjected to 
dissolution testing and the results are shown in Figs. 7–10, according to the type of solvent used 
during the preparation of solid dispersion formulations. The solvents used have different polarity 
which can be ranked as follows: ethanol:water (2:1) > ethanol > acetone:water (2:1) > acetone. The 
dissolution behaviour of pure IND and IND solid dispersions prepared with GLU using acetone (A) 
as the solvent are shown in Figure 7. It is clear that the IND has the slowest dissolution and all solid 
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dispersions have a higher dissolution. Despite the prediction of immiscibility from the Hansen 
solubility parameters, all solid dispersions produced had a significant impact on dissolution 
compared to IND alone or their physical mixture counterparts. The dissolution parameters for the 
solid dispersions of indomethacin are shown in Table 2. Increasing the contribution of carrier from 
2:1 to 1:10 (indomethacin:G-HCl) did not induce any significant dissolution enhancement, as 
Q30min, DE120min, MDT, and MDR had not changed significantly (ANOVA-test, p > 0.05). This 
indicates that the ratio of drug to carrier in the solid dispersion is not one of the main parameters 
controlling the performance of these solid dispersions, and a direct relationship between the amount 
of carrier and indomethacin dissolution could not be established. 
The dissolution profiles of solid dispersions using ethanol with various ratios of drug to carrier are 
shown in Figure 8. The highest dissolution was observed at higher concentration of carrier (drug to 
carrier 1:3, 1:5 and 1:10). No further improvement in dissolution of indomethacin occurred when 
the amount of carrier was increased from 75 % (ratio of drug to carrier 1:3) to 90.9 % (ratio of 
drug:carrier 1:10) (Figure 7 and 8). By comparing the solid dispersions samples produced from 
acetone (Figure 7), with the samples prepared from ethanol (Figure 2), there is no significant 
difference observed in the dissolution of indomethacin when a high concentration of carrier used 
(1:5 or 1:10). When the amount of carrier used was further reduced (2:1 and 1:3), solid dispersion 
samples produced from acetone dissolved faster than the solid dispersion samples produced from 
ethanol. 
At high concentrations of glucosamine, solubility issues meant that it was difficult to dissolve all of 
the glucosamine in acetone or ethanol for preparation of solid dispersion. Water was incorporated in 
the preparation of solid dispersion samples to improve solubility as glucosamine has a high 
solubility in water (320 mg/mL). To prepare this solvent combination, IND was dissolved in 
acetone or ethanol and GLU was dissolved in water (for more details refer to preparation of solid 
dispersions). The dissolution behaviours of indomethacin from these solid dispersions prepared 
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from binary mixtures of A/W and E/W are shown in Figures 9 and 10, respectively. In contrast to 
solid dispersions samples produced from single solvent (Figures 9 and 10), those prepared using 
binary solvents generally had their highest dissolution observed at higher concentration of carrier 
(drug to carrier 1:10), particularly evident for those produced using E/W (Figures 9 and 10). The 
dissolution of indomethacin from physical mixtures showed that, like solid dispersion formulations, 
the presence of glucosamine significantly increased the dissolution of indomethacin (Figure 11). 
The fastest dissolution for physical mixtures of indomethacin:glucosamine was observed when the 
ratio of drug:carrier was 1:10, but was not as enhanced as equivalent solid dispersions, as 
demonstrated by the DE values in Table 2. The use of the various solvents induced polymorphic 
transformations in some of the solid dispersion samples (A, A/W and E). Hancock and Parks, 
(1999) studied the solubility of the different polymorphic forms of indomethacin by inducing the 
metastable α-polymorph of indomethacin from its stable γ-polymorph by precipitation from 
saturated methanol solution with water. They showed the α-polymorph to have an improved 
solubility over the stable γ-polymorph. This shows that the formation of the metastable polymorphic 
may have also contributed to the dissolution enhancement of the solid dispersions. 
To facilitate comparison between solid dispersion and physical mixtures and identification of the 
optimal solvent to prepare indomethacin solid dispersions, DE, MDT and MDR were calculated 
(Table 2).   Solubility parameters were not useful in predicting the miscibility of the IND and GLU 
in the solvent systems. For example, the solubility parameters suggested IND to be soluble in water 
and GLU not to be soluble in water. The results however from Table 2 clearly show that the highest 
dissolution efficiency belongs to the samples prepared from acetone at a ratio of drug to carrier of 
1:3. For the binary solvent solid dispersions, when the ratio of glucosamine was increased, a 
significant increase in dissolution rate of drug was observed (the higher DE and MDR or the lowest 
MDT). Therefore, for the solid dispersions prepared using binary solvents, a high concentration of 
carrier should be used to enhance the dissolution of indomethacin. Generally, the dissolution of 
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indomethacin is faster from solid dispersion samples produced in the presence of binary solvents. 
However, interesting results were obtained when differences in DE were calculated between solid 
dispersion formulations prepared in the presence of acetone or ethanol with those prepared in the 
presence of additional solvent (water) at the same ratio of indomethacin:carrier. These results 
showed that the difference reduces as the contribution of carrier in the solid dispersion increases. 
For example, when the ratio of indomethacin:carrier was 2:1, the difference in DE between solid 
dispersion produced in presence of acetone and acetone:water was +8.9%, whereas at the ratio of 
1:10 this difference was reduced to -9.5%, while in case of ethanol and ethanol/water it increased 
from -27.5 to -11.5 % (Figure 12).  This indicated that in order to increase the dissolution of 
indomethacin from solid dispersions prepared from acetone-water or ethanol-water, the contribution 
of carrier should be high. Independent dissolution parameters (DE, MDR and MDT) usually give an 
overview of the dissolution of a sample throughout the dissolution process, but they do not give an 
insight into the dissolution changes for each time interval. Therefore, Q10min and Q30min (percent 
drug dissolved within 10 and 30 minutes respectively) were calculated (Table 2). 
From Table 2 it is evident that the dissolution of pure indomethacin is very low (less than 32 % 
within 30 min). It can be concluded that all solid dispersions of indomethacin-glucosamine showed 
considerable enhancement in dissolution compared to the physical mixtures. However, the 
dissolution of all physical mixtures was higher compared to pure indomethacin. Possible 
explanations of the increased dissolution rate of solid dispersions have been proposed by Ford 
(1986) and Craig (2002) and include: reduction of drug crystallite size (Table 3, Figure 1 (e and f) 
as evidenced in the SEM images); a solubilisation effect of the carrier; absence of aggregation of 
drug crystallites, improved wettability and dispersibility of the drug; dissolution of the drug in the 
hydrophilic carrier; inhibition of fine particle aggregation; conversion of the drug to the amorphous 
state; and finally a combination of the above mentioned mechanisms. 
Table 2 again shows that in the first 10 min of the dissolution run, solid dispersion samples 
prepared from ethanol/water with ratio of 1:5 produced the fastest dissolution. This is similar to the 
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DE data reported in the same table. When the dissolution data was compared for 30 min dissolution 
(Q30min), the same ratio 1:5 had the fastest dissolution. 
 
4. CONCLUSIONS 
Despite the solubility parameters predicting immiscibility of IND with GLU, the use of GLU had 
significant impact on the triboelectrification and dissolution properties of the dispersion formed. 
GLU significantly enhanced the dissolution rate of indomethacin formulated as solid dispersions. 
The type of solvent used also influenced the rate of dissolution of the solid dispersion, with solid 
state characterization also showing that the method used in producing the solid dispersion had an 
effect on inducing different polymorphic forms of the parent drug. Triboelectrification showed 
indomethacin to have a high propensity for charging with glucosamine having practically no charge 
and being able to form ordered mixtures in its PMs resulting in the PMs of drug and carrier having a 
very low charge. The solid dispersions also exhibited very low net charges with an interesting 
phenomenon observed regarding its charging. Dispersions made from acetone or acetone/water mix 
had an electronegative charge with dispersions from ethanol or ethanol/water displaying 
electropositive charging. As a result of these findings, further studies are being carried out 
simultaneously investigating several solvent effects on solid dispersion charging (also investigating 
polymorphic form contribution to charging as this was outside the scope of this study) and 
dissolution improvement. 
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Table 1. Calculated Hansen solubility parameters for indomethacin and glucosamine 
Sample δd (MPa1/2) δp (MPa1/2) δh (MPa1/2) δt (MPa1/2) Δδ 
IND 18.82 5.06 8.68 21.30 - 
GLU 16.49 17.79 28.24 37.23 15.93 
 
Table 2. Solvent type and its effects on the dissolution parameters of solid dispersions and physical 
mixtures (mean ± SD, n ≥ 3). 
IND:GLU Solvent 
DE120min 
(%) 
MDT 
(min) 
MDR 
(% min
-1
) 
Q10min 
(%) 
Q30min 
(%) 
IND 36.01 21.24 0.37 18.5 ± 2.2 32.2 ± 8.1 
PM 2:1 - 48.36 27.40 0.54 16.6 ± 0.2 37.6 ± 5.5 
PM 1:3 - 53.26 24.38 0.60 22.1 ± 3.4 45.3 ± 8.0 
PM 1:5 - 46.06 24.47 0.50 18.9 ± 0.5 38.4 ± 5.0 
PM 1:10 - 56.36 22.58 0.71 26.0 ± 2.7 50.7 ± 2.1 
E 2:1 Ethanol 54.51 27.37 0.66 17.8 ± 2.3 42.2 ± 3.4 
E 1:3 Ethanol 78.51 17.99 1.11 27.5 ± 0.9 79.3 ± 3.4 
E 1:5 Ethanol 80.95 17.99 1.10 38.8 ± 0.0 78.7 ± 0.0 
E 1:10 Ethanol 84.11 18.68 1.15 43.2 ± 7.8 79.5 ± 15.3 
E/W 2:1 Ethanol/water 82.03 16.85 1.13 41.6 ± 4.9 81.4 ± 3.0 
E/W 1:3 Ethanol/water 91.22 12.52 1.16 56.1 ± 0.5 95.0 ± 0.5 
E/W 1:5 Ethanol/water 94.54 8.10 1.17 78.8 ± 0.0 99.6 ± 0.0 
E/W 1:10 Ethanol/water 95.65 9.29 1.28 74.5 ± 0.0 100.00 ± 0.0 
A 2:1 Acetone 88.54 16.27 1.11 47.8 ± 0.0 87.6 ± 0.0 
A 1:3 Acetone 90.85 15.46 1.26 49.7 ± 0.0 91.7 ± 0.0 
A 1:5 Acetone 85.59 15.28 1.21 44.7 ± 6.7 88.1 ± 5.6 
A 1:10 Acetone 81.58 16.00 1.10 52.7 ± 8.4 80.2 ± 9.1 
A/W 2:1 Acetone/water 79.63 18.31 1.10 35.3 ± 3.0 78.3 ± 5.3 
A/W 1:3 Acetone/water 81.10 17.42 1.10 47.7 ± 8.1 78.6 ± 11.8 
A/W 1:5 Acetone/water 77.88 20.48 1.03 39.5 ± 1.4 71.3 ± 0.3 
A/W 1:10 Acetone/water 91.69 14.02 1.30 57.1 ± 2.5 96.5 ± 7.1 
 
PM = Physical mixture of drug and carrier 
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Table 3. Particle size analysis of physical mixtures and solid dispersion samples of indomethacin 
and glucosamine 
IND:GLU Solvent 
D10% 
(µm) 
D50% 
(µm) 
D90% 
(µm) 
IND - 5.11 27.11 127.38 
GLU - 36.20 252.30 518.39 
PM 2:1 - 6.26 39.54 284.80 
PM 1:3 - 6.74 53.23 224.62 
PM 1:5 - 7.47 58.29 210.9 
PM 1:10 - 30.98 438.44 790.28 
E 2:1 Ethanol 2.16 12.72 232.69 
E 1:3 Ethanol 2.57 20.28 220.45 
E 1:5 Ethanol 6.47 62.17 343.81 
E 1:10 Ethanol 3.68 24.14 136.61 
E/W 2:1 Ethanol/water 1.9 9.82 63.65 
E/W 1:3 Ethanol/water 2.72 24.04 183.56 
E/W 1:5 Ethanol/water 2.79 25.89 179.74 
E/W 1:10 Ethanol/water 2.54 25.65 158.34 
A 2:1 Acetone 2.07 12.33 188.03 
A 1:3 Acetone 6.09 542.32 808.05 
A 1:5 Acetone 3.97 22.8 147.81 
A 1:10 Acetone 6.12 84.4 365.72 
A/W 2:1 Acetone/water 2.80 19.57 145.65 
A/W 1:3 Acetone/water 2.33 18.73 213.91 
A/W 1:5 Acetone/water 2.33 14.18 66.66 
A/W 1:10 Acetone/water 3.85 42.19 330.8 
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Figure 1. SEM images of a) indomethacin, b) glucosamine HCl, c) physical mixture of 
indomethacin-DG (1:3) and solid dispersion of indomethacin:glucosamine HCl (1:3) d) acetone, e) 
ethanol, f) acetone and water, g) ethanol and water. All images are at the same magnification (x500 
with scale bar indicating 50 µm). IND = indomethacin. GLU = glucosamine. 
Figure 2. FT-IR spectra of glucosamine,  indomethacin and solid dispersions of indomethacin:glucosamine 
of ration 1:3, a) glucosamine, b) indomethacin and solid dispersions from c) ethanol 1:3, d) acetone 1:3, e) 
ethanol in water 1:3, f) acetone in water. 
Figure 3. XRPD pattern of the unprocessed Indomethcin, solid dispersions and physical mixtures (PM) of 
indomethacin:glucosamine ratio 1:3 and solid dispersions of indomethacin:glucosamine prepared from 
ethanol (E), ethanol/water (E/W), acetone (A) and acetone/water (A/W) ratio 1:3.  
Figure 4. DSC traces of glucosamine ; indomethacin; physical mixture (PM) of indomethacin-glucosamine 
and solid dispersions of indomethacin:glucosamine prepared from ethanol (E), ethanol/water (E/W), acetone 
(A) and acetone/water (A/W) ratio 1:3.  
Figure 5. Specific charge and polarity for unprocessed indomethacin (IND), glucosamine (GLU), physical 
mixture (PM) of indomethacin-glucosamine and solid dispersions of indomethacin:glucosamine prepared 
from ethanol (E), ethanol/water (E/W), acetone (A) and acetone/water (A/W) all with ratio 1:3.  
Figure 6. Percentage of mass loss for unprocessed indomethacin (IND), glucosamine, (GLU), physical 
mixture (PM) of indomethacin-glucosamine and solid dispersions of indomethacin:glucosamine prepared 
from ethanol (E), ethanol/water (E/W), acetone (A) and acetone/water (A/W) all with ratio 1:3 against 
stainless steel surface after charging.  
Figure 7. Dissolution profiles of indomethacin–glucosamine HCl solid dispersions with different 
ratios of drug:carrier where acetone (A) used as solvent (data are mean and standard deviations of 
three determinations).  
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Figure 8. Dissolution profiles of indomethacin–glucosamine HCl solid dispersions with different 
ratios of drug:carrier where ethanol (E) used as solvent (data are mean and standard deviations of 
three determinations). 
Figure 9. Dissolution profiles of indomethacin–glucosamine HCl solid dispersions made from 
binary mixtures of acetone–water (A/W) with different ratios of drug:carrier where acetone–water 
(A/W) used as solvent (data are mean and standard deviations of three determinations). 
Figure 10. Dissolution profiles of indomethacin–glucosamine HCl solid dispersions made from 
binary mixtures of ethanol–water (E/W) with different ratios of drug:carrier where ethanol–water 
(E/W) used as solvent (data are mean and standard deviations of three determinations). 
Figure 11. Dissolution profiles of indomethacin from physical mixtures (PM) with different ratios 
of drug–glucosamine (data are mean and standard deviations of three determinations). 
Figure 12. Relationship between the differences in dissolution efficiency of solid dispersion produced from 
single solvent and binary solvents and amount of carrier in the formulation. 
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